Sanofi Increases Investment in Nurix-Partnership for STAT6 Program

Sanofi has exercised its option to exclusively license Nurix Therapeutics' STAT6 program, triggering a $15 million license extension payment to Nurix135.

To date, Sanofi has paid Nurix a total of $127 million under their collaboration, with the potential for up to $465 million in future development, regulatory, and commercial milestones13.

The licensed drug candidate, NX-3911, is a potent, oral, highly selective STAT6 degrader aimed at treating inflammation in allergic conditions such as atopic dermatitis and asthma13.

The STAT6 degrader was developed using Nurix’s DEL-AI drug discovery platform and has demonstrated strong efficacy in preclinical models, showing effects equivalent to a complete STAT6 knockout13.

Nurix retains the right to co-develop and co-promote up to two products, including NX-3911, in the U.S.13.

STAT6 is a key transcription factor that mediates IL-4 and IL-13 signaling in type 2 inflammatory diseases, making it a significant therapeutic target for conditions such as asthma and allergies13.

Sources:

1. https://www.nasdaq.com/articles/nurix-therapeutics-secures-15-million-license-extension-sanofi-stat6-program

3. https://www.fiercebiotech.com/biotech/sanofi-pays-15m-another-stat6-degrader-fruitful-nurix-collab

5. https://www.tipranks.com/news/the-fly/oppenheimer-bullish-on-nurix-as-sanofi-opt-in-competitor-data-derisk-stat6-thefly